As of 2026-05-16, the Relative Valuation of BioMark Diagnostics Inc (BUX.CN) is (0.24) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.58 CAD, the upside of BioMark Diagnostics Inc based on Relative Valuation is -141.5%.
The range of the Relative Valuation is (0.20) - (0.28) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.3x - 18.4x | 15.4x |
| Forward P/E multiples | 11.5x - 17.3x | 14.4x |
| Fair Price | (0.20) - (0.28) | (0.24) |
| Upside | -134.2% - -148.2% | -141.5% |
| Date | P/E |
| 2026-05-14 | -35.86 |
| 2026-05-13 | -35.86 |
| 2026-05-11 | -35.86 |
| 2026-05-08 | -35.86 |
| 2026-05-07 | -36.48 |
| 2026-05-06 | -36.48 |
| 2026-05-05 | -35.86 |
| 2026-05-01 | -36.48 |
| 2026-04-28 | -35.86 |
| 2026-04-27 | -35.86 |
| 2026-04-24 | -37.10 |
| 2026-04-23 | -35.24 |
| 2026-04-21 | -35.86 |
| 2026-04-17 | -35.86 |
| 2026-04-15 | -35.86 |
| 2026-04-14 | -36.48 |
| 2026-04-13 | -37.10 |
| 2026-04-08 | -37.10 |
| 2026-04-07 | -37.10 |
| 2026-04-06 | -36.48 |
| 2026-04-02 | -37.10 |
| 2026-04-01 | -35.86 |
| 2026-03-31 | -35.24 |
| 2026-03-30 | -35.86 |
| 2026-03-27 | -37.72 |
| 2026-03-26 | -36.48 |
| 2026-03-25 | -37.72 |
| 2026-03-24 | -37.10 |
| 2026-03-23 | -34.01 |
| 2026-03-20 | -37.10 |
| 2026-03-18 | -37.10 |
| 2026-03-17 | -37.72 |
| 2026-03-16 | -37.10 |
| 2026-03-13 | -38.33 |
| 2026-03-11 | -38.33 |
| 2026-03-10 | -38.33 |
| 2026-03-09 | -37.10 |
| 2026-03-06 | -37.72 |
| 2026-03-05 | -37.72 |
| 2026-03-04 | -38.33 |
| 2026-03-03 | -39.57 |
| 2026-03-02 | -35.86 |
| 2026-02-27 | -35.86 |
| 2026-02-26 | -34.01 |
| 2026-02-25 | -34.63 |
| 2026-02-24 | -35.24 |
| 2026-02-23 | -34.63 |
| 2026-02-20 | -35.24 |
| 2026-02-19 | -35.86 |
| 2026-02-18 | -32.77 |